FDA approves Eylea to treat all stages of diabetic retinopathy

Currently used to treat diabetic macular edema, Eylea recently gained FDA approval for treating all stages of diabetic retinopathy. Eylea works as a “vascular endothelial growth factor (VEGF)” inhibitor by stopping the growth of abnormal blood vessels in the eye. It also reduces swelling and leakage, which are what lead to vision loss. Clinical trials […]

Eye injections have low risk of retinal detachment

Patients with retinal disease who are treated with intravitreal anti-VEGF injections have a lower incidence of retinal detachment according to a recent study

The latest retinal eye treatment is a TRAP!

A new treatment for eye disease is designed to bind all forms of Vascular Endothelial Growth Factor-A (VEGF-A) and Placental Growth Factor (PLGF) proteins which play a part in the abnormal growth of new blood vessels. It is known as VEGF Trap-Eye.